As the treatments for liver disease and the availability of liver transplantation have
progressed, the number of patients with end stage liver disease continues to increase. This
has increased the need to risk-stratify patients with cirrhosis to better direct their
treatments and provide an accurate prognosis for their outcomes. The traditional assessment
of the liver patient has been limited to imaging, static measures of "liver function tests"
and liver biopsy. This protocol is designed to increase the spectrum of tests in the
evaluation of the patient with end stage liver disease.